Editorial: More Information on Prostate Specific Antigen and Prostate Cancer

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles: Editorial1 Aug 2003Editorial: More Information on Prostate Specific Antigen and Prostate Cancer Thomas A. Stamey Thomas A. StameyThomas A. Stamey View All Author Informationhttps://doi.org/10.1097/01.ju.0000077443.49060.83AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Editorial: More Information on Prostate Specific Antigen and Prostate Cancer." The Journal of Urology, 170(2), pp. 457–458 References 1 : Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology; prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol2002; 167: 103. Link, Google Scholar 2 : Preoperative serum prostate-specific antigen (PSA) below 10 μg/L predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem2001; 47: 631. Google Scholar 3 : Limitations of serum PSA below 10 to 12 ng./ml.. AUA News2002; 7: 31. Sep/Oct. Google Scholar 4 : Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar 5 : Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol1997; 157: 2206. Link, Google Scholar 6 : Editorial comment. J Urol2001; 166: 109. Google Scholar 7 : Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer1993; 71: 933. Google Scholar 8 : Effect of aging on morphologic and clinical predictors of prostate cancer progression. The Prostate J2000; 2: 157. Google Scholar 9 : SEER cancer statistics review 1973–1997. http://seer.cancer.gov/publications/csr1973_1997/prostate.pdf. (accessed February 2001). Google Scholar Department of Urology, Stanford University Medical Center, Stanford, California© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byWolters T, Roobol M, van Leeuwen P, van den Bergh R, Hoedemaeker R, van Leenders G, Schröder F and van der Kwast T (2018) A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening TrialJournal of Urology, VOL. 185, NO. 1, (121-125), Online publication date: 1-Jan-2011.AVERNA T, KLINE E, SMITH A and SILLERUD L (2018) A DECREASE IN 1H NUCLEAR MAGNETIC RESONANCE SPECTROSCOPICALLY DETERMINED CITRATE IN HUMAN SEMINAL FLUID ACCOMPANIES THE DEVELOPMENT OF PROSTATE ADENOCARCINOMAJournal of Urology, VOL. 173, NO. 2, (433-438), Online publication date: 1-Feb-2005. Volume 170Issue 2August 2003Page: 457-458 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.MetricsAuthor Information Thomas A. Stamey More articles by this author Expand All Advertisement PDF downloadLoading ...